TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02542475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (\< 100x) than those used in ECT and rTMS.
Study: NCT03090126

Intervention type: OTHER
Intervention: Therapeutic education
Description: Questionnaires
Study: NCT03691974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Subcutaneous (SC) every four weeks (Q4W)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) every four weeks (Q4W)
Study: NCT03678402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUP™ sock
Description: The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
Study: NCT03485833

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEO and EIO test
Description: velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
Study: NCT01030510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the order of drug administration
Description: In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the order of drug administration
Description: In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
Study: NCT01659320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg twice daily for 8 weeks
Study: NCT03889561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drink Tap
Description: The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
Study: NCT01770925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N-CPAP
Description: The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: n-BiPAP
Description: The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water , a peak inspiratory pressure of 9 cm of water, RR of 35 and ti of 0.32
Study: NCT03939507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AEP score available to the treating physician
Description: the treating physician knew the AEP score results
Study: NCT01745146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASMT
Description: 8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRE
Description: 8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
Study: NCT01826747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crinone (progesterone 8%, vaginal application)
Study: NCT03605680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 100 mg, BID, oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID, oral tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BID, oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200 mg, BID, oral tablets
Study: NCT04046679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Skin bleomycin infusion through tattoo machine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bleomycin
Description: Skin bleomycin infusion through tattoo machine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline solution infusion through tattoo machine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution infusion through tattoo machine
Study: NCT04536597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quince seed jelly group
Description: Quince seed jelly, prepared by the researcher, was given to the mothers belonging to this group. Briefly, 3 g (2-3 pieces) of quince seeds are placed in 100 mL water and heated to boiling for 10 min. The prepared quince kernel was used for 3 days, immediately after cooling.14,15 On the 1st day postpartum, the researcher provided the mothers with practical training at the hospital, regarding the application of quince seed jelly to the nipple and areola and leaving it to dry. This training was repeated on the 3rd, 7th and 10th days, to ensure that the mothers followed it precisely. The training process was completed in 5-10 min, including questions and answers. Every 3-4 days (days 1, 3, 7 and 10), quince seed jelly prepared by the researcher was given to the mothers to continue applying, according to the procedure. The mothers were asked to apply it after every breastfeeding.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast milk group
Description: Mothers in this group received practical training, conducted by the researcher on the 1st day postpartum at the hospital, on applying a few drops of their breast milk to the nipples and areola after each breastfeeding and leaving it to dry. This training lasted 5-10 min. Breast milk application of mothers in this group was recorded on the 1st, 3rd, 7th and 10th days, by the researcher.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Any kind of application that the mothers in the control group did for the nipple fissures were recorded on the 1st, 3rd, 7th and 10th days postpartum, by the researcher
Study: NCT03083340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
Study: NCT04450485

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty
Study: NCT02106312

Intervention type: RADIATION
Group type: OTHER
Intervention: dose reduction of preoperative radiotherapy in MLS
Description: A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
Study: NCT03697187

Intervention type: DRUG
Intervention: rhC1INH
Description: Recombinant human C1 inhibitor
Study: NCT02073773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality based therapy
Description: The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
Study: NCT03883880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate
Description: Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin gallate control
Description: Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Description: Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linoleic acid control
Description: Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin solution
Description: Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin control
Description: Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
Study: NCT03582670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Process Training
Description: Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
Study: NCT02177760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT01334034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0123-0000-0338
Description: Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
Study: NCT02524353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac surgery
Description: Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
Study: NCT01931800

Intervention type: BIOLOGICAL
Intervention: Sampling of blood

Intervention type: BIOLOGICAL
Intervention: Sampling of blood

Intervention type: BIOLOGICAL
Intervention: Sampling of blood
Study: NCT03389971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter-directed thrombolysis
Description: catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
Study: NCT03346460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Scraping
Description: Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tongue scraper and aPDT
Description: Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
Study: NCT00954044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Randomized Exercise Intervention
Description: The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Randomized Exercise Intervention
Description: Couples will continue doing their usual daily activities for 6 months
Study: NCT02518009

Intervention type: OTHER
Intervention: Genetic men treated with estrogen
Description: Observational during estrogen treatment

Intervention type: OTHER
Intervention: Genetic women treated with androgen
Description: Observational during androgen treatment
Study: NCT01196052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
Study: NCT01638988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1. cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~2. to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate
Description: Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
Study: NCT01653626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: package of 3 interventions
Description: Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
Study: NCT00905853

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escalated Antiarrhythmic Therapy
Description: Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day
Study: NCT02344888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and Prednisolone
Description: Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene citrate and folic acid
Description: Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)